Skip to main content
. 2016 Jun;33(6):28–34.

Table 2.

FDA-Approved Injectable Disease-Modifying Therapies

Injectable Therapies Dosing Adverse Effects/Warnings/Precautions
Glatiramer acetate33 20 mg SC daily or 40 mg SC 3 times per wk
Indication: relapsing forms of MS
Injection-site reactions
Lipoatrophy
Postinjection systemic reaction (eg, chest pain, palpitations, flushing, anxiety, dyspnea)
Pregnancy Category: B
Interferon beta-1a34 30 mcg IM once per wk
Indication: relapsing forms of MS
Injection-site reactions
Flulike symptoms
Hematologic abnormalities
Elevated liver enzymes
Exacerbation of preexisting thyroid disease
Worsening of mood disorder, including depression/anxiety
Pregnancy Category: C
Interferon beta-1a35 22 mcg or 44 mcg SC 3 times per wk
Indication: relapsing forms of MS
Same as above
Interferon beta-1b36,37 0.25 mg SC every other day
Indication: relapsing forms of MS
Same as above
Peginterferon beta-1a38,39 125 mcg SC every 2 wk
Indication: relapsing forms of MS
Same as above

Abbreviations: IM, intramuscular; SC, subcutaneous; MS, multiple sclerosis.